Biotech RadarJobs updated

COMPANY

Alessa Therapeutics, Inc.

HQ: San Carlos, CA source · alessatherapeutics.com ↗ · West Coast

Clinical Phase 1

Alessa Therapeutics is developing a proprietary drug-delivery platform for sustained and localized release of clinically proven therapies to effectively treat early-stage prostate cancer. From company website Source · Oct 12, 2026

Keywords: Prostate Adenocarcinoma Lower Urinary Tract Symptoms localized prostate cancer prostate cancer enzalutamide

Location: San Carlos, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

3Trials (company is sponsor)2NIH grants

Raises and deals from press releases

Raises announced in these releases: $15M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

  1. Raise Seed · $15M source ↗
  2. Trial start Phase 1: Enzalutamide Implants (Enolen) in Patients With Prostate Cancer source ↗
  3. Trial start Phase 1: Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer source ↗
  4. Trial start Phase 1: A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 3

RecordTitlePhaseStatusStartPrimary completion
NCT06257693Enzalutamide Implants (Enolen) in Patients With Prostate CancerPhase 1RecruitingJun 21, 2024Dec 30, 2028 (estimated)
NCT04943536Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate CancerPhase 1Active, not recruitingDec 7, 2021Apr 24, 2027 (estimated)
NCT04284761A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate CancerPhase 1CompletedOct 11, 2020May 3, 2023 (actual)

NIH awards 2

Annual award amounts. Total $799K.

Feedback